Could a 6-month IV drip help severe heart failure patients avoid death or transplant?
NCT ID NCT00610051
First seen Jan 11, 2026 · Last updated May 23, 2026 · Updated 19 times
Summary
This Phase 3 study tests a continuous 6-month infusion of alprostadil (ALP-1) versus placebo in 600 adults with advanced heart failure and reduced ejection fraction. The goal is to see if the drug can delay death, need for heart transplant, or other major heart events. Participants must have severe symptoms (NYHA class IIIb or IV) and specific lab markers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HFREF - HEART FAILURE WITH REDUCED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical university Vienna
Vienna, Austria
Conditions
Explore the condition pages connected to this study.